New drugs for atopic dermatitis – a chronic rash that falls under the eczema umbrella but can be severe – are poised to launch in 2017 and establish the therapy area as a multi-billion drug category. These include Regeneron Pharmaceuticals Inc./Sanofi’s Dupixent (duplimumab), the first biologic to treat the disease systemically, and Pfizer Inc.’s crisaborole, a novel topical non-steroidal anti-inflammatory.
The therapy area is expected to become a blockbuster-sized drug market because of high demand for effective treatments in a category that has seen little advancement in the last decade
The atopic dermatitis market is expected to grow from approximately $579.2m in 2015 in the US, Japan and five European markets (France, Germany, Italy, Spain and the UK) to $2.1bn in 2024, according to the market research group Datamonitor Healthcare. Growth will be driven by the launch of dupilumab, while sales of the current brand leaders, Astellas Pharma Inc
